ATE335074T1 - Verwendung eines klones von infektiösen und attenuierten typ ii rinderdiarrhöviren um fötal infektion von typ i bvdv zu vermeiden - Google Patents

Verwendung eines klones von infektiösen und attenuierten typ ii rinderdiarrhöviren um fötal infektion von typ i bvdv zu vermeiden

Info

Publication number
ATE335074T1
ATE335074T1 AT02797952T AT02797952T ATE335074T1 AT E335074 T1 ATE335074 T1 AT E335074T1 AT 02797952 T AT02797952 T AT 02797952T AT 02797952 T AT02797952 T AT 02797952T AT E335074 T1 ATE335074 T1 AT E335074T1
Authority
AT
Austria
Prior art keywords
type
diarrhovirus
bvdv
clone
infectious
Prior art date
Application number
AT02797952T
Other languages
English (en)
Inventor
Knut Elbers
Christiane Meyer
Freyburg Martina Von
Gregor Meyers
Original Assignee
Boehringer Ingelheim Vetmed
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmed filed Critical Boehringer Ingelheim Vetmed
Application granted granted Critical
Publication of ATE335074T1 publication Critical patent/ATE335074T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24061—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24361—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT02797952T 2001-09-06 2002-09-05 Verwendung eines klones von infektiösen und attenuierten typ ii rinderdiarrhöviren um fötal infektion von typ i bvdv zu vermeiden ATE335074T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10143813A DE10143813A1 (de) 2001-09-06 2001-09-06 Infektiöser Rindervirusdiarrhoe-Virusklon

Publications (1)

Publication Number Publication Date
ATE335074T1 true ATE335074T1 (de) 2006-08-15

Family

ID=7697990

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02797952T ATE335074T1 (de) 2001-09-06 2002-09-05 Verwendung eines klones von infektiösen und attenuierten typ ii rinderdiarrhöviren um fötal infektion von typ i bvdv zu vermeiden

Country Status (16)

Country Link
EP (2) EP1749885B8 (de)
JP (2) JP4416504B2 (de)
KR (1) KR20040039295A (de)
CN (1) CN1551913A (de)
AR (1) AR036432A1 (de)
AT (1) ATE335074T1 (de)
BR (1) BR0212312A (de)
CA (1) CA2457441C (de)
DE (2) DE10143813A1 (de)
DK (1) DK1749885T3 (de)
ES (1) ES2401072T3 (de)
HU (1) HUP0401585A3 (de)
MX (1) MXPA04002124A (de)
PL (1) PL368748A1 (de)
UY (1) UY27434A1 (de)
WO (1) WO2003023041A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7179473B2 (en) 1998-06-05 2007-02-20 Boehringer Ingelheim Vetmedica Gmbh Attenuated pestiviruses
US7135561B2 (en) 2001-09-06 2006-11-14 Boehringer Ingelheim Vetmedica Gmbh Infectious bovine viral diarrhea virus clone
ES2319424T3 (es) 2003-03-27 2009-05-07 Ottawa Health Research Institute Virus mutantes de la estomatitis vesivular y sus usos.
US7572455B2 (en) 2004-05-19 2009-08-11 Boehringer Ingelheim Vetmedica Gmbh Vaccine comprising an attenuated pestivirus
DE102004025452A1 (de) * 2004-05-19 2006-01-19 Boehringer Ingelheim Vetmedica Gmbh Vakzine enthaltend BVDV
UY29915A1 (es) * 2005-11-15 2007-06-29 Boehringer Ingelheim Vetmed Vacuna combinada que comprende un virus atenuado de la diarrea viral bovina
UY31930A (es) 2008-06-25 2010-01-29 Boheringer Ingelheim Pharma Kg Pestivirus atenuados recombinantes, en particular a csfv, bvdv o bdv atenuado recombinante
KR200451870Y1 (ko) * 2008-07-08 2011-01-14 박윤규 일회용 액상 내용물 용기
CA2744750C (en) * 2008-12-03 2018-10-09 Pfizer Inc. Bovine viral diarrhea virus with a modified erns protein
US8846054B2 (en) 2009-01-09 2014-09-30 Boehringer Ingelheim Vetmedica, Inc. Method of treating pregnant cows and/or heifers
CN101906487A (zh) * 2010-08-05 2010-12-08 中国兽医药品监察所 一种猪瘟病毒核酸标准物质的制备方法
EP2618841B1 (de) 2010-09-21 2016-10-19 Intervet International B.V. Bvdv-impfstoff
US20160120628A1 (en) * 2013-06-12 2016-05-05 The Board Of Regents For Oklahoma State University Fluttering ear tag for bovine vaccination
CN113230394B (zh) * 2021-04-30 2024-04-30 广州源博医药科技有限公司 一种用于牛病毒性腹泻的rna疫苗及其构建方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1104676A1 (de) * 1999-11-30 2001-06-06 Boehringer Ingelheim Vetmedica Gmbh Sichere abgeschwächte Rinderdiarrhöeviren zur Verwendung in trächtigen Kühen

Also Published As

Publication number Publication date
HUP0401585A3 (en) 2005-02-28
EP1749885A2 (de) 2007-02-07
CN1551913A (zh) 2004-12-01
WO2003023041A2 (en) 2003-03-20
EP1440149B1 (de) 2006-08-02
EP1749885A3 (de) 2007-08-29
CA2457441A1 (en) 2003-03-20
DK1749885T3 (da) 2013-03-11
AR036432A1 (es) 2004-09-08
ES2401072T3 (es) 2013-04-16
MXPA04002124A (es) 2004-07-08
JP4416504B2 (ja) 2010-02-17
JP2005502361A (ja) 2005-01-27
BR0212312A (pt) 2004-10-13
EP1749885B8 (de) 2013-01-16
WO2003023041A3 (en) 2003-11-20
CA2457441C (en) 2013-01-08
DE60213639D1 (de) 2006-09-14
HUP0401585A2 (hu) 2004-11-29
EP1440149A2 (de) 2004-07-28
UY27434A1 (es) 2003-04-30
EP1749885B1 (de) 2012-12-05
PL368748A1 (en) 2005-04-04
KR20040039295A (ko) 2004-05-10
DE60213639T2 (de) 2007-10-18
JP2009291203A (ja) 2009-12-17
DE10143813A1 (de) 2003-04-10

Similar Documents

Publication Publication Date Title
ATE335074T1 (de) Verwendung eines klones von infektiösen und attenuierten typ ii rinderdiarrhöviren um fötal infektion von typ i bvdv zu vermeiden
DE60236767D1 (de) Medizinische Verwendung eines TetrahydrotriazoloÄ4,3-aÜpyrazins
ATE438637T1 (de) Thiophenderivate als antivirale mittel gegen flavivirus-infektion
ATE376825T1 (de) Influenzavirus-impfstoffzusammensetzung zur nasalen anwendung
ATE344669T1 (de) 4-fluoro-n-indan-2-yl benzamid und seine verwendung als arzneimittel
IS7479A (is) Afleiður af N-[fenýl(píperidín-2-ýl)metýl]bensamíð, aðferð við framleiðslu þeirra og notkun í læknismeðferðum
JP2002517569A5 (de)
DE60122718D1 (de) Strukturen und zusammensetzungen zur erhöhung der stabilität von aktiven peroxiden
DE60208794D1 (de) 4'-substituierte nukleoside zur behandlung von hepatitis-c-virus-vermittelten erkrankungen
DE60037395D1 (de) Herstellung eines halbleiter-bauelementes
DE60324178D1 (de) THIAZOLIDIN-4-ONES UM hYAK3 PROTEINEN ZU HEMMEN
ATE327765T1 (de) Methoden um rotavirusvarianten zu trennen und lebender attenuierter rotavirus impfstoff
DE50313062D1 (de) Bauteil aus einer Lithiumaluminosilikat-Glaskeramik
DE60112431D1 (de) Verwendung von biguanidederivaten zur herstellung eines vernarbungsfördernden medikaments
DE60114057D1 (de) Schalldämpfer aus einer Titan-Legierung
DE60221874D1 (de) Externes teil einer uhr und verfahren zu herstellung des teils
NO20042156L (no) Piperidinderivater og deres anvendelse som modulatorer av kemokinreseptoraktivitet (spesielt CCRS)
DE60225788D1 (de) Immunassay-verfahren und dabei zu verwendender immunassay-reagenzienkit
DE60040380D1 (de) Gesicherte Typ D Master-Slave Kippschaltung
DE60022155D1 (de) Behandlung von Anrufen in einer Nummernportabilitätsumgebung mittels erzwungener Standardwegelenkung
DE60220988D1 (de) Herstellung und verwendung eines plasmodiumfusionsantigen
DE60017383D1 (de) Selbstklebendes polymerisierbares monomer und damit hergestellte dental/medizinische zusammensetzungen
PL361667A1 (en) Compositions of n-(methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosaccharides
ATE273012T1 (de) Kombinationen von lamivudin und entecavir für behandlung der hepatitis b virus infektion
CO5210951A1 (es) Mezclas fungicidas sinergicas de una azolopirimidina y una fenoxiamida inhibidora de la biosisntesis de melanina

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties